Eton Pharmaceuticals (NASDAQ:ETON) Issues Earnings Results

Eton Pharmaceuticals (NASDAQ:ETON) released its quarterly earnings data on Tuesday. The company reported ($0.02) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.02), Zacks reports. Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%.

Eton Pharmaceuticals Price Performance

Shares of Eton Pharmaceuticals stock opened at $15.29 on Tuesday. The firm’s fifty day simple moving average is $15.40 and its 200-day simple moving average is $11.35. The stock has a market capitalization of $398.32 million, a price-to-earnings ratio of -69.50 and a beta of 1.37. Eton Pharmaceuticals has a 12 month low of $3.03 and a 12 month high of $18.41.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on ETON shares. B. Riley initiated coverage on shares of Eton Pharmaceuticals in a report on Friday, January 10th. They set a “buy” rating and a $21.00 price objective on the stock. HC Wainwright lifted their target price on shares of Eton Pharmaceuticals from $17.00 to $33.00 and gave the company a “buy” rating in a report on Thursday, January 23rd. Finally, Craig Hallum lifted their target price on shares of Eton Pharmaceuticals from $15.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday, January 8th.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.